Charles River Laboratories International, Inc. (NYSE:CRL) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Charles River Laboratories International, Inc. (NYSE:CRL) have been given an average recommendation of “Moderate Buy” by the fifteen research firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have given a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $265.6875.

Several research firms recently weighed in on CRL. Barclays restated an “overweight” rating and set a $300.00 price target on shares of Charles River Laboratories International in a research report on Wednesday, August 5th. Morgan Stanley raised their price objective on Charles River Laboratories International from $260.00 to $300.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Citigroup restated a “buy” rating on shares of Charles River Laboratories International in a report on Wednesday, July 8th. BNP Paribas Exane set a $250.00 target price on shares of Charles River Laboratories International in a research report on Wednesday, July 1st. Finally, JPMorgan Chase & Co. upgraded shares of Charles River Laboratories International from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $180.00 to $310.00 in a research note on Thursday, August 6th.

Charles River Laboratories International Stock Performance

Shares of CRL opened at $278.02 on Friday. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04. Charles River Laboratories International has a one year low of $144.26 and a one year high of $303.30. The company has a 50-day simple moving average of $260.17 and a two-hundred day simple moving average of $205.58. The firm has a market capitalization of $13.27 billion, a PE ratio of -57.32, a price-to-earnings-growth ratio of 2.68 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $980.53 million. During the same quarter in the prior year, the business earned $3.12 EPS. The business’s revenue for the quarter was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, analysts anticipate that Charles River Laboratories International will post 11.33 EPS for the current fiscal year.

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Victoria L. Creamer sold 4,179 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $259.16, for a total transaction of $1,083,029.64. Following the completion of the transaction, the executive vice president owned 30,051 shares of the company’s stock, valued at approximately $7,788,017.16. This trade represents a 12.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Shannon Parisotto sold 2,039 shares of Charles River Laboratories International stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $294.12, for a total transaction of $599,710.68. Following the transaction, the executive vice president owned 4,807 shares of the company’s stock, valued at $1,413,834.84. The trade was a 29.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 165,990 shares of company stock valued at $42,606,388. Insiders own 1.30% of the company’s stock.

Hedge Funds Weigh In On Charles River Laboratories International

Institutional investors and hedge funds have recently modified their holdings of the stock. Empirical Finance LLC lifted its holdings in shares of Charles River Laboratories International by 4.4% during the second quarter. Empirical Finance LLC now owns 1,469 shares of the medical research company’s stock valued at $333,000 after purchasing an additional 62 shares in the last quarter. Glenmede Trust Co. NA lifted its stake in Charles River Laboratories International by 2.8% during the 1st quarter. Glenmede Trust Co. NA now owns 2,706 shares of the medical research company’s stock valued at $467,000 after acquiring an additional 73 shares during the period. Mercer Global Advisors Inc. ADV raised its holdings in shares of Charles River Laboratories International by 1.3% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 6,316 shares of the medical research company’s stock valued at $1,260,000 after purchasing an additional 80 shares during the last quarter. Syon Capital LLC lifted its position in Charles River Laboratories International by 2.4% during the second quarter. Syon Capital LLC now owns 3,547 shares of the medical research company’s stock valued at $804,000 after purchasing an additional 83 shares during the period. Finally, Advisory Services Network LLC boosted its holdings in Charles River Laboratories International by 2.6% in the third quarter. Advisory Services Network LLC now owns 3,226 shares of the medical research company’s stock worth $505,000 after purchasing an additional 83 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a global provider of drug discovery, nonclinical development and laboratory services for pharmaceutical, biotechnology and medical device companies, as well as academic and government research institutions. The company supports customers throughout the development process, from early-stage research and target identification through preclinical testing and regulatory preparation.

Its offerings include research models and related products, discovery and development services, toxicology and safety assessment, efficacy testing, bioanalysis, and laboratory testing.